Table 1.
Cancer Intervention Outcomes of Published Clinical Trials with SeMet/Se-yeast in North America
| Trial | Se form & Dose µg Se/day |
Baseline Se ng/ml |
Post-Rx Se* ng/ml (max) |
Outcome** parameter |
RR*** Rx/Placebo |
1o Ref |
|---|---|---|---|---|---|---|
| Clark NPCT | Se-yeast, 200 | 113 (median) | 190 | PCa (2nd) | 0.37 (p=0.002) | (3) |
| Clark NPCT (follow-up) |
1 tertile, <106 | PCa (2nd) | 0.14 | (5) | ||
| 2 tertile, 107–123 | PCa (2nd) | 0.33 | ||||
| 3 tertile, >123 | PCa (2nd) | 1.14 | ||||
| SELECT | SeMet, 200 | 136 (median) | 251(max283) | PCa (1o) | 1.04 (p>0.15) | (8) |
| SWOG9917 | SeMet, 200 | 137 (median) | 261 (max305) | PCa (1o) | 0.97 (p=0.73) | (9) |
| ECOG NBT | Se-Yeast, 200 | 126 (median) | Not available | PCa (1o) | 0.94 (p=0.18) | (10) |
| Se-Yeast, 400 | Not available | “ “ | 0.90 (p=0.17) | |||
| ECOG5597 | Se-Yeast, 200 | Not available | Lung Ca (1o) | 1.25 (p=0.294) | (11) | |
| Lung Ca |
*
Highest median/mean reported for that study
**
Outcome parameter: planned primary endpoint (1o) vs. added secondary endpoint (2nd) of the respective trial.
The Negative Biopsy Trial (NBT)-US, New Zealand
***
95% Confidence intervals were not presented in most of these studies.